

## Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis


*Ayodeji Adegunsoye, MD; Shehabaldin Alqalyoobi, MD; Angela Linderholm, PhD;  
Willis S. Bowman, MD; Cathryn T. Lee, MD; Janelle Vu Pugashetti, MD; Nandini Sarma, MD;  
Shwu-Fan Ma, PhD; Angela Haczku, MD, PhD; Anne Sperling, PhD; Mary E. Streck, MD;  
Imre Noth, MD; and Justin M. Oldham, MD*


CHEST 2020; 158(4):1526-1534

*Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.*

© 2020 AMERICAN COLLEGE OF CHEST PHYSICIANS. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details. DOI: 10.1016/j.chest.2020.04.066

**e-Figure 1.** Scatterplot of plasma biomarker duplicates.  $R^2 > 0.99$  for each biomarker. |





**e-Figure 2.** Survival among individual AF exposure groups

**e-Table 1.** Propensity matched covariate means, variance and variance ratios

Covariate	AF Exposed		AF Non-exposed		variance ratio
	mean	variance	mean	variance	
white race	0.89	0.1	0.91	0.08	1.23
gap score	4.11	1.76	4.09	1.63	1.08
center	1.74	0.2	1.34	0.23	0.87
smoking history	0.69	0.22	0.59	0.24	0.9

**R-idx bias = 0**

**e-Table 2. Multivariable Adjusted Biomarker Survival Association Stratified by Anti-fibrotic Exposure**

Biomarker	AF Non-exposed (n=172)			AF Exposed (n=68)		
	Optimal threshold	HR	95% CI	Optimal threshold	HR	95% CI
CA-125	225 pg/mL	1.18	0.42-3.32	100 pg/mL	6.63#	1.6-27.5
CXCL13	140 pg/mL	1.45	0.92-2.27	209 pg/mL	3.09	0.89-10.67
MMP7	3.4 ng/mL	1.25	0.78-2.01	5.1 ng/mL	3.45*	1.29-9.22
SP-D	30 ng/mL	1.89	0.97-3.66	33 ng/mL	3.0*	1.01-8.91
YKL-40	85 ng/mL	1.17	0.72-1.91	101 ng/mL	4.28#	1.59-11.53
VCAM-1	1600 ng/mL	2.30#	1.31-4.03	1520 ng/mL	2.1	0.48-9.21
OPN	47 ng/mL	1.42	0.86-2.36	58 ng/mL	5.56*	1.39-23.2

∫ model adjusted for center, race, smoking history and baseline GAP score

\*  $p \leq 0.05$

#  $p \leq 0.01$

**e-Table 3. Biomarker Survival Association Stratified by Anti-fibrotic Exposure Using Non-Censored Follow-up Times**

Biomarker	AF Non-exposed (n=172)			AF Exposed (n=68)		
	Optimal threshold	HR	95% CI	Optimal threshold	HR	95% CI
CA-125	225 pg/mL	2.42	0.98-5.99	100 pg/mL	4.27*	1.23-14.8
CXCL13	140 pg/mL	1.49*	1.0-2.23	209 pg/mL	3.48*	1.25-9.66
MMP7	3.4 ng/mL	1.8#	1.2-2.69	5.1 ng/mL	3.87#	1.58-9.47
SP-D	30 ng/mL	2.36#	1.41-3.96	33 ng/mL	2.04	0.83-4.99
YKL-40	85 ng/mL	1.65*	1.07-2.55	101 ng/mL	4.9#	2.01-11.96
VCAM-1	1600 ng/mL	2.04#	1.22-3.42	1520 ng/mL	2.81	0.82-9.65
OPN	47 ng/mL	1.66*	1.03-2.67	58 ng/mL	3.37*	1.11-10.2

\*  $p \leq 0.05$

#  $p \leq 0.01$